Citi raises its price target on its top pharma pick,

Divi’s Laboratories has a high potential to become a primary supplier given its capacity addition, Citi said in its note, further adding that Orforglipron, Eli Lilly’s potential best-in-class oral GLP-1, is the next addition in Divi’s Laboratories’ pipeline.

Source